### **Overview** Gufic BioSciences Ltd is one of India’s top 100 pharmaceutical companies and a leading global manufacturer of complex, differentiated injectables, with operations spanning India, Europe, South Africa, Canada, Brazil, and other emerging markets. The company operates across **four core business pillars**: Critical Care, Assisted Reproductive Technologies (ART), Toxins (Aesthetic & Neurology), and Science-Based Nutraceuticals. It combines branded domestic sales, contract manufacturing (CMO), and international business with a focus on innovation, regulatory excellence, and supply chain resilience. Gufic continues to strengthen its position as a **global provider of high-quality, affordable life-saving medicines**, leveraging cutting-edge facilities, a robust R&D pipeline, and strategic international partnerships. --- ### **Strategic Growth & Market Expansion** - **Global Market Aspirations**: Gufic aims to capture **5–10% market share** in targeted international geographies over the next 3–5 years, focusing on EU, LATAM, and other regulated markets. - **Regulatory Momentum**: - Secured **24 product and facility approvals** in H1 2025 across South Africa, Colombia, Portugal, etc. - Achieved **210+ product registrations globally**, with **150+ in the pipeline across 40+ countries**. - Gufic Ireland secured its **first EU marketing authorization** and filed two products in 18 EU countries. - **UK NHS and Global Tenders**: Supply to the UK NHS has begun in FY25–26, validating quality in highly regulated markets. The company won a national tender in Sri Lanka and secured a major global health partnership for a complex injectable across **109 public health markets worldwide**. --- ### **Manufacturing & Capacity Expansion** - **Navsari (Gujarat)**: A fully automated, **EU-GMP-certified facility** for lyophilized injectables. It produces APIs and formulations for regulated exports and supports advanced molecules in anti-infectives, oncology, and infertility. - **Indore (Madhya Pradesh) – Flagship Expansion**: The **state-of-the-art Unit III**, operational since October 2024, is one of India’s most advanced lyophilized injectable plants. - Monthly capacity: - 5M lyophilized vials - 6M liquid vials - 10M ampoules - **145 state approvals secured**; **40 products tech-transferred**, 27 in development. - On track for **EU GMP/MHRA clearance by Q1 FY27** and **30% capacity utilization by FY26**. - **De-bottlenecking & Export Growth**: Scaling at Indore will free up **Navsari’s capacity** for export-focused manufacturing, enabling higher profitability and global supply expansion. --- ### **Key Business Divisions & Therapeutic Focus** #### 1. **Critical Care (Criticare & Sparsh)** - Focus on **anti-infectives, immunology, cardiac, and critical care injectables**. - Portfolio includes: - **Cavim** (Ceftazidime + Avibactam): #1 in its class across 195+ hospitals. - **Dalbavancin**: India’s first once-weekly injectable; gaining traction in corporate hospitals. - **Immunocin-Alpha**: Approved by DCGI for **sepsis immunomodulation**—a first-of-its-kind in India. - Advanced delivery systems: - **Dual Chamber Bags (DCBs)** and **Dual Chamber Syringes** for sterility and dosing precision. - S-Pantoprazole and Meropenem-DCB launched successfully. #### 2. **Women’s Health & Fertility (Ferticare & Zenova)** - **Ferticare Cluster**: - Offers **ultra-purified HMG (Supergraf)**, **Guficin Alpha (Thymosin for RIF)**, **recombinant FSH**, and **hormonal formulations**. - Achieved **over 50% YoY growth**, with **strong brand momentum**: - Puregraf: On track for ₹25 Cr annual revenue - Cetrocare: Aiming for top-3 positioning - Supergraf: Targeting ₹15 Cr in two years - **Precision Immunotherapy**: Biomarker-based patient screening improves implantation success. - **Zenova**: - Focused on **ortho-gynaec**, **infertility**, and **menopause care**. - Launched **Fertiforce-M/F** (antioxidants), **Polmaxib-P** (pain), and **Vonoprazan (VonHa)**. - Achieved **30% YoY growth in Q1 FY26** and expanded OPD outreach via 394 campaigns. #### 3. **Aesthetic & Neurology (Aesthaderm & NeuroCare)** - **Aesthaderm**: - India’s **first indigenous Botulinum Toxin Type A (Stunnox)**, now used by **1,000+ practitioners**. - Expanding into **dermal fillers, skin boosters, and biostimulators** via global in-licensing. - Building a **full-stack aesthetics ecosystem** with clinics, training (GROW), and branded protocols. - **NeuroCare**: - **Zarbot**, the therapeutic Botulinum Toxin A, holds **17% market share** in therapeutics. - Largest dedicated neurology team in India covering **neurology, urology, ophthalmology, and pain**. - Pipeline includes **IVIg, Type E toxin, and topical formulations**. #### 4. **Nutraceuticals & Ayurvedic Wellness (Sallaki, Gufisan, Gufican)** - **"Ayurveda++"** initiative: Science-backed modernization of Ayurvedic therapies. - **Sallaki® (Boswellia serrata)** platform dominates joint and bone health; Sallaki MR and Liniment hold **top 3 rankings**. - Expanded into: - **Gufican Oil**: India’s first **4% Cannabis sativa oil** for arthritis. - **Gufispon**: Herbal cure for **cervical spondylosis** with 28% repeat prescribing. - **Vonoprazan (Vonobase/VonHa)**: Tapping ₹1,000+ Cr acid suppression market. --- ### **Innovation & R&D Pipeline** - **R&D Infrastructure**: - Over **50 major R&D projects** in pipeline, including **recombinant FSH, peptides, liposomal, and sustained-release technologies**. - 5 granted patents; 8+ in process across oncology, immuno-oncology, and reproductive medicine. - **Peptide & API Development**: - Investment in **internal API manufacturing** for **peptides and cyclopeptides** to ensure supply resilience. - API capabilities in **antifungal, anticoagulant, antidiabetic, beta-agonist, and tetracycline antibiotics**. - **Advanced Drug Delivery**: - Dual chamber syringes, microspheres, liposomal formulations, depot injections. - In-house device development (e.g., Stretchmark Meter for Stretchnil). --- ### **Oncology & Immuno-Oncology (Selvax Collaboration)** - Gufic holds exclusive Indian rights and 50% revenue share in Europe for **Selvax’s cancer immunotherapy**. - **Preclinical data**: - 80% tumor clearance in mesothelioma models. - **100% cure in pancreatic cancer** vs. 0% with standard chemo. - **Canine trials** showed **68.4% clinical benefit**, 25% complete remission. - **Pipeline molecules**: - **SVX-1001** (murine), **SVX-2001** (canine), **SVX-3001 (humanized anti-CD40)** in development. --- ### **Contract Manufacturing (CMO) Leadership** - Over **70 domestic and global clients** served. - A leading supplier of: - **Tigecycline** - **Gonadotropins** - **Liposomal Amphotericin B (GufiSome)** - **Micafungin** - **Remdesivir** - Serves as a **trusted CMO partner** for complex generics and niche molecules. --- ### **Commercial Strength & Market Reach** - **Domestic Presence**: - Reaches **30,000+ retail outlets**, **120,000+ doctors**, and **80% of tertiary hospitals**. - Sales force: **Critical Care (250 reps), Nutraceuticals (>300), Infertility (>150), Ortho-Gynae (60), Dermo-Cosmetics (40)**. - **Sparsh Division**: - Direct-to-hospital model with **1,400+ hospital relationships**. - Launched **contrast media**, **albumin**, and **nutritional injectables**. - Achieved full tertiary **sales visibility**—a rare industry differentiator. - **GROW & Training Programs**: - **GROW Symposium**, cadaver labs, and workshops to train over **600 injectors** in aesthetics and neurology. - Drives adoption, safe use, and long-term prescription loyalty.